IDH1 R132C in glioma — non-canonical; same therapeutic implications as R132H (vorasidenib...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-IDH1-R132C-GBM |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-GBM |
| Sources | SRC-CIVIC SRC-EANO-GBM-2024 SRC-NCCN-CNS-2025 |
Actionability Facts
| Biomarker | BIO-IDH-MUTATION |
|---|---|
| Variant | IDH1 R132C |
| Disease | DIS-GBM |
| ESCAT tier | IIA |
| Recommended combinations | vorasidenib |
| Evidence summary | IDH1 R132C in glioma — non-canonical; same therapeutic implications as R132H (vorasidenib). |
Notes
ESCAT IIA. Non-R132H variants missed by IHC — require sequencing.
Used By
No reverse references found in the YAML corpus.